Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2022

View Archived Issues

Accumulation of aberrant acylation PTMs on critical metabolic enzymes underlies MMA

Q-griffithsin: an antiviral lectin for COVID-19

Vanderbilt University patents new muscarinic M4 receptor antagonists

Deciphera Pharmaceuticals discloses PERK and/or GCN2 inhibitors

Beijing Jacobio Pharmaceuticals identifies new GTPase KRAS inhibitors

A&J Science synthesizes new antibacterials

National Center for Geriatrics & Gerontology synthesizes acyclic retinoid derivatives

Aqilion receives clearance for phase I study of AQ-280 for eosinophilic esophagitis

ADGRL1 haploinsufficiency linked to neurodevelopmental disorders

T3SS inhibitor MBX-5452 well tolerated and reduces bacterial load in pneumonia mouse model

Merck KGaA collaborates with University of Bonn on tools for computational chemistry modeling

Gain-of-function p.Glu1099Lys variant in the NSD2 gene tied to novel syndrome

Scientists discover new mechanism that causes cardiac hypertrophy in response to pressure overload

Variants in the FOSL2 gene cause a new neurodevelopmental disorder

TAMM41 gene variation associated with neonatal mitochondrial disease

Omega Therapeutics files IND for OTX-2002 for HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...